




Polyposis in children, and the CHIP study

Dr Warren Hyer
Consultant Paediatric Gastroenterologist
Northwick Park and St Mark's Hospital





Attenuated FAP



1580 Attenuated FAP




1395 Desmoid 2000




457 CHRPE 1444

Natural history of paediatric FAP




? Too early



Too late?






But when will a patient develop a cancer?

Table 3 Proportion of FAP patients with CRC diagnosed at ≤ 20 years of age*


Polyposis registry	Total number of CRCs	Number of CRCs (%) diagnosed		
		0–10 years	11–15 years	16–20 years
The Netherlands	106	0	1	1
Denmark	190	0	0	3
Germany	524	0	1	7
St Mark's	96	0	0	3
Finland	157	0	0	1
Total	1073	0	2 (0.2%)	15 (1.3%)

Guidelines for the clinical management of familial adenomatous polyposis (FAP)

H F A Vasen,¹ G Möslein,² A Alonso,³ S Aretz,⁴ I Bernstein,⁵ L Bertario,⁶ I Blanco,⁷ S Bülow,⁸ J Bum,⁹ G Capella,¹⁰ C Colas,¹¹ C Engel,¹² I Frayling,¹³ W Friedl,⁴ F J Hes,¹⁴




Colectomy in adolescents- IRA or IPAA? St Mark's approach



Complications of Childhood Peutz-Jeghers Syndrome: Implications for Pediatric Screening

*R. Hinds, †C. Philp, †W. Hyer, and *J. M. Fell


**Department of Paediatric Gastroenterology, Chelsea and Westminster Hospital, London; and the †The Polyposis Registry, St. Mark's Hospital, London, England*



The end of the barium in PJS.....VCE is not perfect enough.....

ABSTRACT


Video Capsule Endoscopy in the management of children with Peutz-Jeghers Syndrome: a blinded comparison with Barium Enterography for the detection of small bowel polyps.



Postgate A, Hyer W, Phillips R, Brown G, Schofield G, Burling D, Gupta A, Marshall M, Bartram C, Taylor S, Latchford A, Bassett P, Fitzpatrick A, **Fraser C**



Close correlation between MRI and capsule endoscopy in adults (and children) with PJS. Gut 2009 Postgate A et al (n=9)



DBE= double balloon enteroscopy
IOE = intra-operative enteroscopy
MRE = magnetic resonance enterography

Double balloon enteroscopy in children

Adult case series/reports:

Small-Intestinal Peutz-Jeghers Polyps Resected by Endoscopic Polypectomy with Double-Balloon Enteroscopy and Removal Confirmed by Ultrasonography



Y. Matsumoto · N. Manabe · S. Tanaka · A. Fukumoto ·
T. Yamaguchi · M. Shimamoto · M. Nakao ·
Y. Mitsuoka · K. Chayama

- But how big a polyp can we resect without injury to the submucosa?
- Lacking evidence and experience with DBE, and polypectomy in PJS in children





Fig. 5 DBE image showed that the polyp was resected, and the ulcer was clipped

What polyp is too big in a child?



Closer prediction about surgical/endoscopic choices



Surgery in PJS



Juvenile polyposis



Unwinding the Heterogeneous Nature of Hamartomatous Polyposis Syndromes

John M. Carethers, MD

IN ANY CLASSIC "WHODUNIT" MYSTERY, THE GOAL OF THE investigator is to find and expose the guilty party. At the onset, there may be many suspects, some of whom may appear guilty. However, the shrewd investigator picks through those distractors to clearly eliminate them and

focuses on specific details to finally identify the true culprit. The same approach holds for the recognition of the hamartomatous polyposis syndromes, many of which demonstrate phenotypic features that overlap with each other.

Author Affiliations: Department of Medicine and Rebecca and John Moores Comprehensive Cancer Center, University of California, San Diego; Veterans Administration Research Service, San Diego.

Corresponding Author: John M. Carethers, MD, GI Section, 111D, Veterans Administration San Diego Healthcare System, 3350 La Jolla Village Dr, San Diego, CA 92161 (jcarethers@ucsd.edu).


See also p 2465.

2498 JAMA, November 16, 2005—Vol 294, No. 19 (Reprinted)

©2005 American Medical Association. All rights reserved.

Issues for the severe infantile juvenile polyposis /Bannayan- Riley-Ruvalcaba

Unpicking the hamartomous syndromes – 21st century style



What genetics?

- LKB1
 - PJS
- PTEN
 - 85% of Cowden
 - 65% of Bannayan Riley Ruvalcaba syndrome
 - JPS
- SMAD 4
 - 20-50% JPS
- BMPR1A
 - 20-40% of JPS
- ENG
 - JPS, HHT

Diagnosis of juvenile polyposis made at colonoscopy and histology

Determine type of JPS –
by clinical presentation
+/- genetic investigation

Screen family
members by genetic
testing if mutation
found, or
colonoscopy

Colonoscopy and polypectomy
every 2-3 years plus gastroscopy

Adequate control of polyp
number and size – continue
screening every 2-3 years

Unable to control symptoms or
polyps are too numerous


Consider colectomy with
ileorectal anastomosis



Now the chance for
adenoma prevention?

THE EFFECT OF CELECOXIB, A CYCLOOXYGENASE-2 INHIBITOR, IN FAMILIAL ADENOMATOUS POLYPOSIS

GIDEON STEINBACH, M.D., PH.D., PATRICK M. LYNCH, M.D., J.D., ROBIN K.S. PHILLIPS, M.B., B.S., MARINA H. WALLACE, M.B., B.S., ERNEST HAWK, M.D., M.P.H., GARY B. GORDON, M.D., PH.D., NAOKI WAKABAYASHI, M.D., PH.D., BRIAN SAUNDERS, M.D., YU SHEN, PH.D., TAKASHI FUJIMURA, M.D., LI-KUO SU, PH.D., AND BERNARD LEVIN, M.D.



How might Coxibs cause increased MI risk

- Depression of I₂ prostaglandin formation
- Elevate blood pressure
- Accelerate atherogenesis
- Thus exaggerated thrombotic response

“The higher a patient’s intrinsic risk of cardiovascular disease
The more likely it would be that such a hazard would manifest itself
Rapidly in the form of a clinical event”

insignificant
in an adolescent

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Celecoxib for the Prevention of Colorectal Adenomatous Polyps

Nadir Arber, M.D., Craig J. Eagle, M.D., Julius Spicak, M.D., István Rácz, M.D.,

The NEW ENGLAND
JOURNAL of MEDICINE

ESTABLISHED IN 1812

AUGUST 31, 2006

VOL. 355 NO. 9

Celecoxib for the Prevention of Sporadic Colorectal Adenomas

Monica M. Bertagnolli, M.D., Craig J. Eagle, M.D., Ann G. Zauber, Ph.D., Mark Redston, M.D.,




Adenoma prevention with sulindac

The New England Journal of Medicine

PRIMARY CHEMOPREVENTION OF FAMILIAL ADENOMATOUS POLYPOSIS WITH SULINDAC

FRANCIS M. GIARDIELLO, M.D., VINCENT W. YANG, M.D., PH.D., LINDA M. HYLIND, B.S., R.N., ANNE J. KRUSH, M.S., GLORIA M. PETERSEN, PH.D., JILL D. TRIMBATH, M.S., STEVEN PIANTADOSI, M.D., PH.D., ELIZABETH GARRETT, PH.D., DEBORAH E. GEIMAN, M.S., WALTER HUBBARD, PH.D., G. JOHAN A. OFFERHAUS, M.D., M.P.H., PH.D., AND STANLEY R. HAMILTON, M.D.

Sulindac did not slow the development of adenomas



Effect of Sulindac on Rectal Polyps in Pediatric APC Carriers


N = 41

Age = 8-25 yrs

Placebo, sulindac 75 mg or 150 mg BID

Flexible sigmoidoscopy q 4 months

End of study Effect on Adenomas	Sulindac N=21 (%)	Placebo N =20 (%)
0	12 (57)	9 (45)
1-10	3 (14)	6 (30)
Adenoma \geq 2.5 mm	4 (19)	7 (35)
Tubular Adenoma	9 (43)	11 (55)



The Safety and Efficacy of Celecoxib in Children With Familial Adenomatous Polyposis

Patrick M. Lynch, MD, JD¹, Gregory D. Ayers, MS², Ernie Hawk, MD, MPH³, Ellen Richmond, RN, MSN³, Craig Eagle, MD⁴, Mabel Woloj, PhD⁴, James Church, MD⁵, Hennie Hasson, RN⁶, Sherri Patterson, RN⁷, Elizabeth Half, MD⁸ and Carol A. Burke, MD⁸

Table 1. Celecoxib dose assignments by body weight and cohort

	Cohort 1, <i>n</i> =6 (2:1 drug: placebo)	Cohort 2, <i>n</i> =6 (2:1 drug: placebo)	Cohort 3, <i>n</i> =6 (2:1 drug: placebo)
Body weight	Celecoxib dose 4 mg/kg	Celecoxib dose 8 mg/kg	Celecoxib dose 16 mg/kg
25.0–37.5 kg	50 mg BID	100 mg BID	200 mg BID
37.6–50.0 kg	100 mg BID	150 mg BID	300 mg BID
>50.0 kg	100 mg BID	200 mg BID	400 mg BID




Figure 2. Celecoxib dose–response relationship among pediatric patients with familial adenomatous polyposis. The number of polyps at baseline

THE POLYPOSIS REGISTRY



S^TMARK'S

HOSPITAL



CHIP

Children's International
Polyposis Trial

- Sue Clark & Professor Phillips
- Warren Hyer, Jo Rawlings, Chris Fraser
- Polyposis Registry, St Mark's Hospital